株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

世界の公共医療関連の提携条件・契約

Global Public Health Partnering 2010-2016: Deal trends, players and financials

発行 Current Partnering, a division of Wildwood Ventures Limited 商品コード 263938
出版日 ページ情報 英文
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
世界の公共医療関連の提携条件・契約 Global Public Health Partnering 2010-2016: Deal trends, players and financials
出版日: 2016年09月01日 ページ情報: 英文
概要

当レポートでは、世界の公共医療関連市場における企業提携の締結動向とその内容(提携条件)について分析し、近年の企業提携/取引形成状況とその特徴(種類別・開発段階別・適応症別)、平均的な取引条件、代表的な資本取引の概略、大手医薬品企業の動向、近年の提携取引一覧とその内訳といった情報を盛り込んで、概略以下の内容でお届けいたします。

エグゼクティブ・サマリー

第1章 イントロダクション

第2章 公共医療関連の取引形成の動向

  • イントロダクション
  • 過去数年間の公共医療関連の提携動向
  • 大手製薬企業の公共医療関連の取引形成活動
  • 公共医療関連の取引に参加していない大手製薬企業
  • 公共医療関連の提携:取引の種類別
  • 公共医療関連の提携:産業分野別
  • 公共医療関連の提携:開発段階別
  • 公共医療関連の提携:技術の種類別
  • 公共医療関連の提携:適応症別
  • 公共医療関連の提携の平均的な取引条件
    • 取引総額 (headline values)
    • 前払い金
    • マイルストーン払い
    • ロイヤルティ率

第3章 代表的な公共医療関連の資本取引

  • イントロダクション
  • 代表的な資本取引:金額別
  • 代表的な資本取引:大手製薬企業が関係するもの

第4章 大手製薬企業の公共医療関連の資本取引

  • イントロダクション
  • 大手製薬企業との提携取引の活用方法
  • 大手製薬企業各社のプロファイル(全31社)

第5章 公共医療関連の提携契約の一覧

  • イントロダクション
  • 取引の種類別
  • 開発・治験の段階別
  • 技術の種類別の一覧

第6章 治療標的別の取引形成

  • イントロダクション
  • 治療標的別の資本取引
    • 公共医療
    • 喫煙依存症
    • 麻薬中毒
    • アルコール中毒
    • 肥満
    • 医療教育
    • 予防医療

第7章 提携リソースセンター

  • オンライン提携
  • 提携関連イベント
  • 関連調査

付録

  • 付録1 公共医療関連の資本取引の一覧:企業名別(A〜Z)、通算7年間分
  • 付録2 公共医療関連の資本取引の一覧:取引の種類別、通算7年間分
  • 付録3 公共医療関連の資本取引の一覧:開発段階別、通算7年間分
  • 付録4 公共医療関連の資本取引の一覧:技術の種類別、通算7年間分
  • 付録5 資本取引の種類

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: CP2222

‘Global Public Health Partnering 2010-2016: Deal trends, players and financials’ provides comprehensive understanding and unprecedented access to the public health partnering deals and agreements entered into by the worlds leading healthcare companies

‘Global Public Health Partnering 2010 to 2016’ provides the full collection of Public Health disease deals signed between the world's pharmaceutical and biotechnology companies since 2010.

  • Trends in Public Health partnering deals
  • Financial deal terms for headline, upfront and royalty by stage of development
  • Public Health partnering agreement structure
  • Public Health partnering contract documents
  • Top Public Health deals by value
  • Most active Public Health dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor's product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Public Health disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Public Health deals.

The report presents financial deal terms values for Public Health deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling readers to analyse and benchmark the value of current deals.

The initial chapters of this report provide an orientation of Public Health dealmaking trends.

Chapter 1 provides an introduction to the report.

Chapter 2 provides an overview of the trends in Public Health dealmaking since 2010 covering trends by year, deal type, stage of development, technology type and therapeutic indication.

Chapter 3 includes an analysis of financial deal terms covering headline value, upfront payment, milestone payments and royalty rates.

Chapter 4 provides a review of the leading Public Health deals since 2010. Deals are listed by headline value. The chapter includes the top 25 most active Public Health dealmakers, together with a full listing of deals to which they are a party. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 5 provides comprehensive access to Public Health deals since 2010 where a deal contract is available, providing the user with direct access to contracts as filed with the SEC regulatory authorities. Each deal title links via Weblink to an online version of the deal record contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive directory of all Public Health partnering deals by specific Public Health target announced since 2010. The chapter is organized by specific Public Health therapeutic target. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

In addition, a comprehensive appendix is provided with each report of all Public Health partnering deals signed and announced since 2010. The appendices are organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc) and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Public Health partnering and dealmaking since 2010.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Public Health technologies and products.

Report scope

‘Global Public Health Partnering 2010 to 2016’ is intended to provide the reader with an in-depth understanding and access to Public Health trends and structure of deals entered into by leading companies worldwide.

‘Global Public Health Partnering 2010 to 2016’ includes:

  • Trends in Public Health dealmaking in the biopharma industry since 2010
  • Analysis of Public Health deal structure
  • Access to headline, upfront, milestone and royalty data
  • Access to hundreds of Public Health deal contract documents
  • Comprehensive access to over 3500 Public Health deal records
  • The leading Public Health deals by value since 2010
  • Most active Public Health dealmakers since 2010

The report includes deals for the following indications: Addiction, Smoking, Drugs, Alcohol, Health education, Obesity, Preventative medicine, plus other public health indications.

In ‘Global Public Health Partnering 2010 to 2016’, available deals and contracts are listed by:

  • Headline value
  • Upfront payment value
  • Royalty rate value
  • Stage of development at signing
  • Deal component type
  • Technology type
  • Specific therapy indication

Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

The ‘Global Public Health Partnering 2010-2016’ report provides comprehensive access to available deals and contract documents for over 200 public health deals. Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are the sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Benefits

‘Global Public Health Partnering 2010 to 2016’ provides the reader with the following key benefits:

  • In-depth understanding of Public Health deal trends since 2010
  • Access Public Health deal headline, upfront, milestone and royalty data
  • Research hundreds of actual contracts between Public Health partner companies
  • Comprehensive access to over 750 links to actual Public Health deals entered into by the world's biopharma companies
  • Indepth review of Public Health deals entered into by the top 25 most active dealmakers
  • Benchmark the key deal terms companies have agreed in previous deals
  • Identify key terms under which companies partner Public Health opportunities
  • Uncover companies actively partnering Public Health opportunities

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Public Health dealmaking

  • 2.1. Introduction
  • 2.2. Public Health partnering over the years
  • 2.3. Public Health partnering by deal type
  • 2.4. Public Health partnering by industry sector
  • 2.5. Public Health partnering by stage of development
  • 2.6. Public Health partnering by technology type
  • 2.7. Public Health partnering by therapeutic indication

Chapter 3 -Financial deal terms for Public Health partnering

  • 3.1. Introduction
  • 3.2. Disclosed financials terms for Public Health partnering
  • 3.3. Public Health partnering headline values
  • 3.4. Public Health deal upfront payments
  • 3.5. Public Health deal milestone payments
  • 3.6. Public Health royalty rates

Chapter 4 - Leading Public Health deals and dealmakers

  • 4.1. Introduction
  • 4.2. Most active in Public Health partnering
  • 4.3. List of most active dealmakers in Public Health
  • 4.4. Top Public Health deals by value

Chapter 5 - Public Health contract document directory

  • 5.1. Introduction
  • 5.2. Public Health partnering deals where contract document available

Chapter 6 - Public Health dealmaking by therapeutic target

  • 6.1. Introduction
  • 6.2. Deals by Public Health therapeutic target

Appendices

  • Appendix 1 - Directory of Public Health deals by company A-Z 2010 to 2016
  • Appendix 2 - Directory of Public Health deals by deal type 2010 to 2016
  • Appendix 3 - Directory of Public Health deals by stage of development 2010 to 2016
  • Appendix 4 - Directory of Public Health deals by technology type 2010 to 2016
  • Further reading on dealmaking
  • Deal type definitions

About Wildwood Ventures

  • Current Partnering
  • Current Agreements
  • Recent report titles from CurrentPartnering

Table of figures

  • Figure 1: Public Health partnering since 2010
  • Figure 2: Public Health partnering by deal type since 2010
  • Figure 3: Public Health partnering by industry sector since 2010
  • Figure 4: Public Health partnering by stage of development since 2010
  • Figure 5: Public Health partnering by technology type since 2010
  • Figure 6: Public Health partnering by indication since 2010
  • Figure 7: Public Health deals with a headline value
  • Figure 8: Public Health deals with upfront payment values
  • Figure 9: Public Health deals with milestone payment
  • Figure 10: Public Health deals with royalty rates
  • Figure 11: Active Public Health dealmaking activity- 2010 to 2016
  • Figure 12: Top Public Health deals by value since 2010
Back to Top